Conclusion:Current evidence indicates that tacrolimus may achieve comparable or higher remission rates than cyclosporine, with fewer total reported adverse events.However, the available data are limited by small sample sizes, heterogeneous study designs, and variable reporting quality, with inconsistent statistical significance.Robust, adequately powered randomized controlled trials are needed to establish the true comparative efficacy and safety of these agents.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Sethi et al. (Wed,) studied this question.